A simplified tumour model established via Epstein-Barr virus-encoded, nasopharyngeal carcinoma-derived oncogene latent membrane protein 1 in immunocompetent mice

Laboratory Animals

Volumn 42, Issue 2, 2008, Pages 193-203

  Chow, Kai Ping N ^a   Wu, C C ^a   Chang, H Y ^b   Chang, C ^c   Chang, Y S ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Epstein Barr virus (EBV); Nasopharyngeal carcinoma; Oncogene latent membrane protein 1 (N LMP1); Tumour mouse model

Indexed keywords

LATENT MEMBRANE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER INCIDENCE; CARCINOGENESIS; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; IMMUNE SYSTEM; IMMUNOCOMPETENCE; MALE; MEDICAL RESEARCH; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; ONCOGENE; PROTEIN EXPRESSION; T CELL DEPLETION;

ANIMALS; BALB 3T3 CELLS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA, NEOPLASM; IMMUNOCOMPETENCE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSFECTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4; MUS; MUS MUSCULUS;

EID: 44649194459     PISSN: 00236772     EISSN: None     Source Type: Journal    
DOI: 10.1258/la.2007.006037     Document Type: Article

References (32)

1. Baichwal VR, Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2, 461-7
2. Burrows JM, Bromham L, Woolfit M, et al. (2004) Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. Journal of Virology 78, 7131-7
3. Busson P, Keryer C, Ooka T, et al. (2004) EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends in Microbiology 12, 356-60
4. Chen ML, Tsai CN, Liang CL, et al. (1992) Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7, 2131-40
5. Edwards RH, Sitki-Green D, Moore DT, et al. (2004) Potential selection of LMP1 variants in nasopharyngeal carcinoma. Journal of Virology 78, 868-81
6. Fang CY, Chang YS, Chow KP, et al. (2004) Construction and characterization of monoclonal antibodies specific to Epstein-Barr virus latent membrane protein 1. Journal of Immunological Methods 287, 21-30
7. Gires O, Zimber-Strobl U, Gonnella R, et al. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO Journal 16, 6131-40
8. Hu L, Troyanovsky B, Zhang X, et al. (2000) Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and negative nasopharyngeal carcinoma. Cancer Research 60, 5589-93
9. Hu LF, Zabarovsky ER, Chen F, et al. (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. Journal of General Virology 72, 2399-409
10. Kaye KM, Izumi KM, Kieff E (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America 90, 9150-4
11. Khanna R, Burrows SR, Nicholls J, et al. (1998) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. European Journal of Immunology 28, 451-8
12. Li HP, Chang YS (2003) Epstein-Barr virus latent membrane protein 1: structure and functions. Journal of Biomedical Sciences 10, 490-504
13. Li SN, Chang YS, Liu ST (1996) Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12, 2129-35
14. Lin JC, Cherng JM, Lin HJ, et al. (2004) Amino acid changes in functional domains of latent membrane protein 1 of Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: prevalence of an HLA A2-restricted 'epitope-loss variant'. Journal of General Virology 85, 2023-34
15. Lin SY, Tsang NM, Kao SC, et al. (2001) Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head and Neck 23, 194-200
16. Mantovani A, Sozzani S, Locati M, et al. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 23, 549-55
17. Miller WE, Edwards RH, Walling DM, et al. (1994) Sequence variation in the Epstein-Barr virus latent membrane protein 1. Journal of General Virology 75, 2729-40
18. Niedobitek G, Agathanggelou A, Nicholls JM (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Seminars in Cancer Biology 7, 165-74
19. Ochsenbein AF, Klenerman P, Karrer U, et al. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proceedings of the National Academy of Sciences of the United States of America 96, 2233-8
20. Ochsenbein AF, Sierra S, Odermatt B, et al. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-64
21. Pan J, Burdick MD, Belperio JA, et al. (2006) CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. Journal of Immunology 176, 1456-64
22. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 4, 71-8
23. Raab-Traub N (2002) Epstein-Barr virus in the pathogenesis of NPC. Seminars in Cancer Biology 12, 431-41
24. Singh S, Ross SR, Acena M, et al. (1992) Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. Journal of Experimental Medicine 175, 139-46
25. Speiser DE, Miranda R, Zakarian A, et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. Journal of Experimental Medicine 186, 645-53
26. Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nature Medicine 10, 294-8
27. Spiotto MT, Yu P, Rowley DA, et al. (2002) Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737-47
28. Trivedi P, Hu LF, Chen F, et al. (1994) Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. European Journal of Cancer 30A, 84-8
29. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831-40
30. Yoshizaki T, Horikawa T, Qing-Chun R, et al. (2001) Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clinical Cancer Research 7, 1946-51
31. Yu JS, Tsai HC, Wu CC, et al. (2002) Induction of inducible nitric oxide synthase by Epstein-Barr virus B95-8-derived LMPl in BALB/3T3 cells promotes stress-induced cell death and impairs LMP1-mediated transformation. Oncogene 21, 8047-61
32. Yu P, Rowley DA, Fu YX, et al. (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion in Immunology 18, 226-31